Soon Milestone will report pivotal data with etripamil, an intranasal heart arrhythmia therapy, and an FDA adcom approaches for Transmedics' heart preservation…
After spending years insisting that its cholesterol-lowering medicine has a place between statins and PCSK9 inhibitors, Esperion must now prove it.
Medtronic has lined up a whole pipeline of new devices – and it will need them.
Drug developers have directed almost half of their dealmaking firepower at oncology projects over the past five years, with cardiovascular a distant second.
Heart failure data must repay Bayer and Merck & Co for taking a chance on vericiguat, and a hit for Medtronic’s renal denervation system could erase the shame of its…
Thales, the final Brilinta outcome trial in Astrazeneca’s huge Parthenon programme, has hit – but the UK group’s vast investment in its blood thinner has yet to pay off.
With Reva, Amaranth and Abbott out of the game, the pool of dissolving scaffold makers is shrinking.
Bayer and Merck & Co need Vitality data to breathe life into vericiguat, while Akero awaits its first big test with the Nash project AKR-001.
Amarin must hope that setbacks for Astrazeneca and Acasti show that in Vascepa it has the secret sauce.